PacificHealth Laboratories Promotes Fred Duffner, Current Senior Vice President of Sales, to President
28 1월 2010 - 11:00PM
Business Wire
PacificHealth Laboratories, Inc. (OTCBB: PHLI), a nutrition
technology company, today announced that Fred Duffner has been
promoted to President reporting directly to the Board of Directors
as well as appointed to the Board following the mutual separation
from the Company of former CEO and President Jason Ash. Mr. Ash
also resigned from the Board of Directors but will remain as an
Executive Advisor for a transitional period.
Before joining PacificHealth in August 2008 as Senior Vice
President of Sales, Mr. Duffner directed his own sales and
marketing company, Duffner & Associates, servicing several
clients including NutriSystem Inc. Prior to founding Duffner &
Associates in 2004, Mr. Duffner was Senior Vice President of
Customer Management at Atkins Nutritionals for 4 years, responsible
for the expansion into the food, drug, and mass channels and
growing their sales volume 10 times to over $500 million. Prior to
Atkins, Mr. Duffner was responsible for total sales of the Revlon
Beauty Business where he had spent 13 years.
Fred Duffner, the new President of PacificHealth Laboratories
said, “I would like to thank Jason for his leadership over the past
two years which has returned PacificHealth back to a leadership
position in sports nutrition. Our team delivered its highest annual
revenue in 2009 while recording double digit growth. I look forward
to working with the management team and the Board of Directors in
continuing the momentum we have built over the past two years and
in achieving profitability.”
About the
Company:
PacificHealth Laboratories, Inc. (PHLI.OB), a leading nutrition
technology company, has been a pioneer in discovering, developing
and commercializing patented, protein-based nutritional products
that stimulate specific peptides involved in appetite regulation
and that activate biochemical pathways involved in muscle
performance and growth. PHLI’s principle areas of focus include
weight loss, management of Type 2 diabetes and sports performance.
To learn more, visit www.pacifichealthlabs.com.
Notice: This news release and oral statements made from time to
time by Company representatives concerning the same subject matter
may contain so-called "forward-looking statements". These
statements can be identified by introductory words such as
"expects", "plans", "will", "estimates", "forecasts", "projects" or
words of similar meaning and by the fact they do not relate
strictly to historical or current facts. Forward-looking statements
frequently are used in discussing new products and their potential.
Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a
broad variety of risks and uncertainties, some of which are known,
such general economic conditions, consumer product acceptance and
competitive products, and others of which are not. No
forward-looking statements are a guarantee of future results or
events, and one should avoid placing undue reliance on such
statements.
PacificHealth Laboratories (CE) (USOTC:PHLI)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
PacificHealth Laboratories (CE) (USOTC:PHLI)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
